Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2019 Aug;17(8):769-770.
doi: 10.1111/ddg.13901_g.

Möglichkeiten und Grenzen von prognostischen Gensignaturen im frühen Melanom

[Article in German]
Markus V Heppt, Carola Berking
Editorial

Möglichkeiten und Grenzen von prognostischen Gensignaturen im frühen Melanom

[Article in German]
Markus V Heppt et al. J Dtsch Dermatol Ges. 2019 Aug.
No abstract available

PubMed Disclaimer

References

Literatur

    1. Gershenwald JE, Scolyer RA, Hess KR et al. Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin 2017; 67(6): 472-492.
    1. Weber J, Mandala M, Del Vecchio M et al. Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma. N Engl J Med 2017; 377(19): 1824-1835.
    1. Eggermont AMM, Blank CU, Mandala M et al. Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanoma. Eur J Cancer 2019; 116: 148-157.
    1. Maio M, Lewis K, Demidov L et al. Adjuvant vemurafenib in resected, BRAF(V600) mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. Lancet Oncol 2018; 19(4): 510-520.
    1. Long GV, Hauschild A, Santinami M et al. Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma. N Engl J Med 2017; 377(19): 1813-1823.

Publication types

LinkOut - more resources